Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cancer diagnostics company Clarient and Definiens, an enterprise image intelligence company, have established a strategic partnership to employ a series of image analysis platforms for Clarient's in-house R&D, and web-based customer portal PATHSiTESM.
Subscribe to our email newsletter
Under a five year collaborative agreement, Clarient and Definiens plan to develop and commercialize tools that will help to evaluate quantitative biomarkers that predict cancer treatment response to targeted therapies.
The partnership with Definiens involves seamlessly integrating a wide range of image analysis tools into Clarient’s existing infrastructure. It is designed to allow Clarient to increase operational throughput with rapid, automated analysis of tissue sample images of all sizes, supporting cancer tissue biomarker profiling and facilitating more streamlined diagnoses.
Gregg Westerbeck, vice president and general manager for Americas at Definiens, said: “The partnership with Clarient will allow us to access to the clinical marketplace, allowing both companies to commercialize translational medicine applications. Clarient’s extensive menu of biomarkers as well as its rapidly growing customer base will extend the reach of our applications.”